Introduction
Breast cancer remains the leading cause of cancer diagnosis and cancer-related death in women, world-wide. Mortality from breast cancer in the western hemisphere has recently showed a trend of decline, understandably this being a result attributable to effective screening and early detection programs, health awareness, access to health-care and a better health-care infrastructure. Developing world has on the other hand shown an increasing mortality, perhaps as a result of lack of availability of factors mentioned for the west, as well increasing "westernization" of the life-style. [1] De novo geographical factors are also considered to be an important contributor for outcomes from breast cancer.
The incidence of breast cancer varies almost 10 fold if data were compared from different countries. [2] Comparison of breast cancer data from various geographic locations is also considered to be important to understand underlying causes of disease or the reasons of death. [3] Pakistan is a developing country, where health-care access is limited and fragmented. Population based registries report the age-standardized incidence of 9.1/100,000 for breast cancer, which is the highest reported from the area and is considerably higher than the much more populous neighboring India. [4] The Aga Khan university Hospital is the largest private medical hospital, in the country and is located in the city of Karachi in Southern Pakistan. It receives patients from all over the country. [4] The comprehensive cancer care services make it a reliable cancer care center in the country. [5] This report covers different aspects of breast cancer observed at our institution, from demographic features, histopathological subtypes, treatment modalities, patterns and incidence of relapse and the treatment strategies in the metastatic setting, as well as the survival.
Materils and Methods
Data were analyzed retrospectively. The diagnoses are stored electronically using international classification of diseases version 9/10. Clinical data on consecutive patients admitted to the hospital between January 1999 and November 2008 and diagnosed to have invasive breast cancer were retrieved. Patients who were diagnosed with the disease earlier, but experienced relapse during the study period were also included. The hospital is one of the few hospitals providing comprehensive cancer care (surgery, chemotherapy, radiotherapy, palliative care, screening and molecular testing) in Pakistan. Majority of the patients included were diagnosed and treated at our hospital. For patients who had been initially diagnosed elsewhere, all specimens were reviewed by the pathology department for verification of diagnosis, immunohistochemistry (IHC) for estrogen receptor (ER), progesterone (PR) and Her2/neu status or fluorescence in situ hybridization (FISH) for Her2/neu gene, where indicated.
The medical records of all patients with a diagnosis of invasive breast cancer were reviewed and information was extracted on to a pre-designed database. Variables included age, gender, date of diagnosis, side of involvement; histopathological type of tumor; tumor size (clinical and pathological), lymph node involvement; number of lymph nodes removed, tumor grade, lymphovascular invasion, ER status, PR status, and Her2/neu status. Clinical and pathological stages were determined using the 6 th edition of American Joint Committee on Cancer (AJCC) manual. The date of last follow-up exam, date and site of relapse and date of death, when relevant were also recorded. The relapses were confirmed from the hospital records and during patient follow-up in clinics (not described for patients who lost to follow-up) and death was also confirmed either form the hospital records or through phone calls. 
Results

Clinical features
A total of 845 patients were included diagnosed to have breast cancer in the study period while remaining 10 patients were diagnosed earlier, but included in the study as they received treatment for disease relapse. All but two were females; the median age at the diagnosis was 48 years (range 18-92 years). The majority of patients were between the ages 40 and 60 years (n = 515, 60.9%), 15% had a family history of breast cancer, 45.7% of all patients were pre-menopausal while remaining had achieved menopause prior to diagnosis. Almost half of the patients (50.5%) had left-sided breast cancer [ Table 1 ].
Pathological features
Clinical and pathological stages are summarized in Table 2 . Merely 9.9% patients presented with clinical Stage I disease (according to AJCC manual, 6 th edition), clinically, T4 disease was detected in 21.1% patients; only 12.1% of patients presented with clinical T1 lesion at the time of diagnosis. Likewise, 43.5% patients had clinically palpable nodes. Pathologically mean tumor size was 4.11 cm [ Table 2 ]. Microscopically, 42.1% patients had involved lymph nodes, the mean number of involved nodes was 6 (range 0-33). More than 93% of the patients had infiltrating ductal carcinoma as the pathological diagnosis, while infiltrative lobular carcinoma (2.7%) was the next common type. Almost a quarter (25.9%) of patients had poorly differentiated cancer and lymphovascular invasion was seen in 15.1% specimens.
ER status was expressed by 51.6% tumors, whereas, PR was expressed by 44%. Data on HER-2/neu status was available for 488 (57.7%) patients; 13.1% patients expressed the protein using the IHC method, whereas, for another (4.5%) patients the gene could be detected using FISH, leading to an overall expression rate of 17.6%. Triple negative disease was diagnosed for 130 (15.3%) patients [ Table 3 ].
For patients presenting with Stage IV disease at presentation (n = 117, 13.8%), bone was the most common site of distant disease (n = 74, 63.2%), followed by lungs (n = 40, 34.1%); more than one organ was involved in 34 patients (29.0%).
Treatment
Of all patients with localized or locally advanced disease at presentation (n = 728, 86.2%), 502 (68.9%) were treated with adjuvant chemotherapy. For patients who presented with metastatic disease (n = 117, 14.1%), palliative chemotherapy or hormonal therapy was administered to 95 (81.2%) patients, 37 patients declined chemotherapy while four patients moved from the hospital before the initiation of treatment.
Out of 728 patients with non-metastatic disease on presentation, 265 (36.4%) patients had locally advanced disease (cT3 or positive nodes clinically) and 195 (73.5%) of these were treated with neo-adjuvant chemotherapy. 
Relapse patterns and survival
All patients were followed at regular intervals in clinics, until the time of death or until they lost to follow-up with median follow-up of 29 months (range 1-224 months).
135 (135/728 = 18.5%) patients experienced relapse (local, loco-regional or distant). Distant recurrence was documented in 69 (9.5%) while 22 (3.0%) had a local recurrence. Bone, lungs and brain were the main sites of relapse. Most of the patients were treated with chemotherapy or radiotherapy while some patients were treated with combination treatment [ Table 5 ]. Of all patients treated for relapsed disease, 32 progressed, 12 had a partial response, 5 had minimal response and 4 had stable disease while 1 had a complete response. 11 patients were treated after complete surgical removal of their relapsed disease and were in remission until the last follow-up. Figure 1 ].
Stage at presentation (P ≤ 0.01), clinical and pathological tumor size (P ≤ 0.01), clinical and pathological node status (P ≤ 0.01), tumor grade (P ≤ 0.01), lymphovascular invasion (P = 0.001), ER status (P = 0.02), radiation therapy (P ≤ 0.01) and hormonal therapy (P ≤ 0.01) were significant factors for OS on univariate analysis.
Clinical stage at presentation (P ≤ 0.01), pathological nodal status (P ≤ 0.01), ER status (P ≤ 0.01) were significant predictive factor for OS on multivariate analysis.
Discussion
The outcomes from breast cancer depend on multiple factors. Breast cancer biology including clinical stage, pathological subtype, hormonal and Her2/neu status are major contributors. Personal factors such as age, body mass index and race are also important. Socioeconomic factors, such as, access to the health-care, ability to afford appropriate treatment and facilities for screening and long-term follow-up and management are much less addressed.
[6] A comprehensive 10-year data is presented from Southern Pakistan. The data focuses on most common aspects of concern in breast cancer. The series reveal a younger mean age at presentation, i.e., 48 years as compared to 61 years reported in the surveillance epidemiology and end results (SEER) data. [7] Our data conform to the data from Karachi cancer registry, a population based registry representing a sample population from all parts of Pakistan, which showed that more than 60% of breast cancer patients were below 50 years [8] and other studies reported form the country and surprisingly the age at presentation has remained almost same in last few decades. [9] [10] [11] The age distribution curve is also similar to the data from most neighboring countries, including those from Arabian peninsula [12] and the east Asia. [13] A small number of patients (9.9%) presented with Stage I disease, while nearly half (48.5%) had Stage II disease, which seems to be similar with SEER data; where 60% of patients are diagnosed to have the localized disease, but differs widely in advanced stage disease as 5% patients had Stage IV disease at presentation in SEER data as compared to 14.1% in our study. This highlights the changes in the trends perhaps set by screening programs and early stage detection. [14, 15] A diagnosis at an early stage is a strong negative predictor of recurrence and therefore improves the long-term survival. [9, 16] The number of patients presenting with Stage IV disease in our study were more than double compared with the western literature (14% vs. 5%). Even for patients with non-metastatic disease a significant number had advanced tumor size (T4 lesions). Once staged our patients did not show vastly different pattern in terms of number and size of the lymph nodes involved and with the mean number of lymph nodes involved when compared with data presented by Carter et al. [17] In comparison to contemporary data the hormone receptor status was found to be lower in our population with over half of all patient's tumors expressed ER, whereas, 44% expressed PR receptors.
Most of our patients underwent MRM, with trends for breast conserving surgery relatively underutilized in most clinical situations which reflects the same trend in other institutions offering breast cancer surgery in the country. [11, 18] A high success rate for sentinel lymph node biopsy has been previously reported from our institute already. [19] Neo-adjuvant chemotherapy was effectively utilized in almost three quarters of patients with locally advanced disease. A combination of adriamysin and cyclophohomide (AC) was the most commonly used chemotherapy regimen. Less than 3.6% of the patient received epirubicin. The reasons remain speculative; however, slightly higher unit cost compared to doxorubicin may have contributed. Not all patients could afford taxane based chemotherapy. Close to 24% managed to get a taxane combination when it was required either in the adjuvant or in the metastatic setting. Trastuzumab is now considered as an integral part of management regimen in Her2/neu over expressing breast cancers. A majority of our patients however could not afford to take adjuvant trastuzumab and in fact a very few actually received the drug for 1 year in the adjuvant setting. Financial difficulties leading to inability to receive standard adjuvant treatment affects the OS in developing countries, or where there is a lack of widespread health insurance system. Tamoxifen was the most favored hormonal agent prescribed. Regardless of the menopausal status, a trend which is consistent with practice observed by physicians world-wide and reported by us previously. [20] Our patients showed a 3% over all incidence of local relapse compared to international report of 5% as reported in National Surgical Adjuvant Breast and Bowel Project NSABP-04 for adequately treated patient, with matching figures for distant recurrences as well. [21] In our data series on a 10 year follow-up breast cancer, survival rates match the survival rates reported internationally and regionally [ Figure 1 ]. [21, 22] The data presented has limitations, including a possible inherent bias of being from a single institution; it nevertheless represents a significant contribution as south Karachi, our sample population, is considered to be the habitat of a population representative of the whole of the country of Pakistan. [23] Although the data presented here, may not be a complete representation of the prevailing trends of breast cancer in Pakistan, it however should contribute immensely to the existing scarce information on patterns and trends of the population from the subcontinent. The fact that the data set is perhaps the largest coming out from any single institution in Pakistan, makes it distinct. The patterns that have come to light by this study highlight the needs of further large scale population based studies to be done so that cost-effective guidelines on breast cancer care are made specific to the needs of this population.
Though the World Health Organization has mentioned about the age distribution of cancer for Pakistan and available cancer treatment facilities it does not mention the outcome at large and our data may help to establish or provide a platform for implementation of the guide lines for the breast cancer treatment in the country, but may also help to focus on the population screening in future. [24] It should also be noted that our institution plays key role in cancer registry through its wide laboratory network across the country through, which large number of pathology specimen are sent to the pathology laboratory, which help to assess the cancer burden in the country. [4] 
Conclusion
In conclusion, this data set presented from a 10 years follow-up of breast cancer patients at our institute suggests that breast cancer appears at relatively younger age and relatively advanced stage of the disease. The pathologic and biologic parameters show some distinct patterns from the region. Treatment modalities offered are according to the internationally accepted standards, but affordability and availability of the same remains restricted for most population. Despite these factors an overall trend of matching survival are found in comparison to regional and international data with regards to survival, however further large scale studies and comparative analysis are needed to improve the assessment of epidemiological and survival trends of our population.
